Emerging markets

Top 10 rare disease pharma sees 10.4% rise in therapy start

Top 10 rare disease pharma sees 10.4% rise in therapy start

By Liza Laws

A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and personalized communications.

CBD-based formulations from dsm-firmenich at CPHI 2024

CPHI 2024

CBD-based formulations from dsm-firmenich at CPHI 2024

By Liza Laws

At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.